Which has better valuation and earnings, OCS or OTLK?

Oncobiologics has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 517.02 -$119.44M -$2.13 N/A Oncobiologics $1.35M 190.42 -$62.42M -$1.17 N/A

Is OCS or OTLK more profitable?

Oncobiologics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oncobiologics' return on equity of 0.00% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Oncobiologics N/A N/A -291.28%

Oncobiologics (OTLK) Competitors

$1.73 +0.18 (+11.61%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$1.72 0.00 (-0.29%)

As of 07/14/2026 07:59 PM Eastern

Compare

OTLK vs. SPRY, ZVRA, OCS, GYRE, and ESPR

Should you buy Oncobiologics stock or one of its competitors? MarketBeat compares Oncobiologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncobiologics include ARS Pharmaceuticals (SPRY), Zevra Therapeutics (ZVRA), Oculis (OCS), Gyre Therapeutics (GYRE), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.

How does Oncobiologics compare to ARS Pharmaceuticals?

Oncobiologics (NASDAQ:OTLK) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Oncobiologics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Oncobiologics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Oncobiologics' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Oncobiologics currently has a consensus price target of $6.50, suggesting a potential upside of 275.72%. ARS Pharmaceuticals has a consensus price target of $28.20, suggesting a potential upside of 270.57%. Given Oncobiologics' higher possible upside, analysts plainly believe Oncobiologics is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Oncobiologics. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 2 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 1.26 beat ARS Pharmaceuticals' score of 0.57 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Overall Sentiment
Oncobiologics	Positive
ARS Pharmaceuticals	Positive

Oncobiologics has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	190.42	-$62.42M	-$1.17	N/A
ARS Pharmaceuticals	$84.28M	8.97	-$171.30M	-$2.01	N/A

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Oncobiologics and ARS Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Zevra Therapeutics?

Oncobiologics (NASDAQ:OTLK) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Zevra Therapeutics has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	190.42	-$62.42M	-$1.17	N/A
Zevra Therapeutics	$106.47M	7.25	$83.23M	$1.99	6.56

Oncobiologics has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Zevra Therapeutics has a net margin of 101.58% compared to Oncobiologics' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Oncobiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Zevra Therapeutics	101.58%	51.49%	28.86%

Oncobiologics presently has a consensus price target of $6.50, suggesting a potential upside of 275.72%. Zevra Therapeutics has a consensus price target of $29.29, suggesting a potential upside of 124.24%. Given Oncobiologics' higher probable upside, equities analysts clearly believe Oncobiologics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Zevra Therapeutics had 2 more articles in the media than Oncobiologics. MarketBeat recorded 4 mentions for Zevra Therapeutics and 2 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 1.26 beat Zevra Therapeutics' score of 0.89 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Overall Sentiment
Oncobiologics	Positive
Zevra Therapeutics	Positive

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Zevra Therapeutics beats Oncobiologics on 13 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Oculis?

Oculis (NASDAQ:OCS) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Oncobiologics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oncobiologics' return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Oncobiologics	N/A	N/A	-291.28%

Oculis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

In the previous week, Oculis had 2 more articles in the media than Oncobiologics. MarketBeat recorded 4 mentions for Oculis and 2 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 1.26 beat Oculis' score of 0.78 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oculis	Positive
Oncobiologics	Positive

22.3% of Oculis shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Oncobiologics has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	517.02	-$119.44M	-$2.13	N/A
Oncobiologics	$1.35M	190.42	-$62.42M	-$1.17	N/A

Oculis presently has a consensus price target of $38.33, suggesting a potential upside of 196.47%. Oncobiologics has a consensus price target of $6.50, suggesting a potential upside of 275.72%. Given Oncobiologics' higher probable upside, analysts plainly believe Oncobiologics is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Oncobiologics beats Oculis on 9 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Gyre Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 168.14%. Oncobiologics has a consensus price target of $6.50, indicating a potential upside of 275.72%. Given Oncobiologics' higher probable upside, analysts plainly believe Oncobiologics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Gyre Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Gyre Therapeutics has higher revenue and earnings than Oncobiologics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.06	$5.03M	-$0.09	N/A
Oncobiologics	$1.35M	190.42	-$62.42M	-$1.17	N/A

In the previous week, Gyre Therapeutics and Gyre Therapeutics both had 2 articles in the media. Gyre Therapeutics' average media sentiment score of 1.94 beat Oncobiologics' score of 1.26 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Very Positive
Oncobiologics	Positive

Oncobiologics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Oncobiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Oncobiologics	N/A	N/A	-291.28%

Summary

Gyre Therapeutics beats Oncobiologics on 11 of the 15 factors compared between the two stocks.

How does Oncobiologics compare to Esperion Therapeutics?

Oncobiologics (NASDAQ:OTLK) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Oncobiologics presently has a consensus price target of $6.50, suggesting a potential upside of 275.72%. Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 74.21%. Given Oncobiologics' higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Esperion Therapeutics had 4 more articles in the media than Oncobiologics. MarketBeat recorded 6 mentions for Esperion Therapeutics and 2 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 1.26 beat Esperion Therapeutics' score of 1.22 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Overall Sentiment
Oncobiologics	Positive
Esperion Therapeutics	Positive

Oncobiologics has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Esperion Therapeutics has higher revenue and earnings than Oncobiologics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	190.42	-$62.42M	-$1.17	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

Esperion Therapeutics has a net margin of 0.12% compared to Oncobiologics' net margin of 0.00%. Oncobiologics' return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Summary

Esperion Therapeutics beats Oncobiologics on 8 of the 14 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OTLK vs. The Competition

Export

Metric	Oncobiologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$230.31M	$3.68B	$6.85B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-1.48	20.98	27.01	24.38
Price / Sales	190.42	311.11	522.34	92.57
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	-2.88	8.54	10.80	6.33
Net Income	-$62.42M	$23.83M	$3.59B	$331.02M
7 Day Performance	2.37%	-2.77%	-1.49%	-0.33%
1 Month Performance	49.14%	5.85%	2.79%	-1.29%
1 Year Performance	-23.79%	52.15%	28.56%	21.30%

Oncobiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OTLK Oncobiologics	3.7298 of 5 stars	$1.73 +11.6%	$6.50 +275.7%	-25.4%	$230.31M	$1.35M	N/A	20	Positive News
SPRY ARS Pharmaceuticals	3.2541 of 5 stars	$8.33 -2.7%	$28.20 +238.5%	-57.5%	$850.04M	$84.28M	N/A	90
ZVRA Zevra Therapeutics	4.352 of 5 stars	$13.97 -0.1%	$29.29 +109.6%	+2.1%	$826.43M	$106.47M	11.01	20	Analyst Upgrade
OCS Oculis	3.022 of 5 stars	$13.80 -2.3%	$38.33 +177.8%	-28.8%	$818.74M	$1.45M	N/A	2	Positive News Analyst Downgrade
GYRE Gyre Therapeutics	2.5165 of 5 stars	$7.26 -1.1%	$17.00 +134.2%	-16.7%	$818.33M	$116.59M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OTLK) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncobiologics (OTLK) Competitors

OTLK vs. SPRY, ZVRA, OCS, GYRE, and ESPR

How does Oncobiologics compare to ARS Pharmaceuticals?

Summary

How does Oncobiologics compare to Zevra Therapeutics?

Summary

How does Oncobiologics compare to Oculis?

Summary

How does Oncobiologics compare to Gyre Therapeutics?

Summary

How does Oncobiologics compare to Esperion Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncobiologics (OTLK) Competitors

OTLK vs. SPRY, ZVRA, OCS, GYRE, and ESPR

How does Oncobiologics compare to ARS Pharmaceuticals?

Which has more risk and volatility, OTLK or SPRY?

Is OTLK or SPRY more profitable?

Do analysts prefer OTLK or SPRY?

Does the media prefer OTLK or SPRY?

Which has better valuation & earnings, OTLK or SPRY?

Do insiders & institutionals have more ownership in OTLK or SPRY?

Summary

How does Oncobiologics compare to Zevra Therapeutics?

Which has stronger earnings & valuation, OTLK or ZVRA?

Which has more volatility and risk, OTLK or ZVRA?

Is OTLK or ZVRA more profitable?

Do analysts rate OTLK or ZVRA?

Does the media favor OTLK or ZVRA?

Do institutionals and insiders hold more shares of OTLK or ZVRA?

Summary

How does Oncobiologics compare to Oculis?

Is OCS or OTLK more profitable?

Which has more volatility and risk, OCS or OTLK?

Does the media favor OCS or OTLK?

Do insiders and institutionals have more ownership in OCS or OTLK?

Which has better valuation and earnings, OCS or OTLK?

Do analysts rate OCS or OTLK?

Summary

How does Oncobiologics compare to Gyre Therapeutics?

Do analysts prefer GYRE or OTLK?

Do institutionals and insiders hold more shares of GYRE or OTLK?

Which has more volatility and risk, GYRE or OTLK?

Which has better earnings & valuation, GYRE or OTLK?

Does the media favor GYRE or OTLK?

Is GYRE or OTLK more profitable?

Summary

How does Oncobiologics compare to Esperion Therapeutics?

Do analysts recommend OTLK or ESPR?

Do insiders and institutionals hold more shares of OTLK or ESPR?

Does the media favor OTLK or ESPR?

Which has more risk and volatility, OTLK or ESPR?

Which has stronger valuation & earnings, OTLK or ESPR?

Is OTLK or ESPR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools